DermAll nanomedicine for allergen-specific immunotherapy by Garaczi, Edina et al.
POTENTIAL CLINICAL RELEVANCE
Nanomedicine: Nanotechnology, Biology, and Medicine
9 (2013) 1245–1254Research Article
DermAll nanomedicine for allergen-specific immunotherapy
Edina Garaczi, MD, PhD
a,b,c
, Kornélia Szabó, PhD
a,c
, László Francziszti, MSc
a,d
,
Zsolt Csiszovszki, PhD
b,c
, Orsolya Lőrincz, MScb,c, Enikő R. Tőke, PhDb,c,
Levente Molnár, MSc
b,c
, Tamás Bitai, MSc
b,c
, Tamás Jánossy, MD, PhD
e
,
Zsuzsanna Bata-Csörgő, MD, DSca, Lajos Kemény, MD, DSca,d,⁎, Julianna Lisziewicz, PhDb,c
aDepartment of Dermatology and Allergology, University of Szeged, Szeged, Hungary
bGenetic Immunity, Budapest, Hungary
cMcLean, VA, USA
dDermatological Research Group of the Hungarian Academy of Sciences, University of Szeged, Szeged, Hungary
eInstitute of Surgical Research, University of Szeged, Szeged, Hungary
Received 27 December 2012; accepted 27 May 2013
nanomedjournal.comAbstract
Allergen-specific immunotherapy (ASIT) the only disease-modifying treatment for IgE-mediated allergies is characterized with long
treatment duration and high risk of side effects. We investigated the safety, immunogenicity and efficacy of a novel ASIT, called DermAll, in
an experimental allergic rhinitis model. We designed and characterized DermAll-OVA, a synthetic plasmid pDNA/PEIm nanomedicine
expressing ovalbumin (OVA) as model allergen. DermAll-OVA was administered topically with DermaPrep device to target Langerhans
cells. To detect the clinical efficacy of DermAll ASIT we quantified the nasal symptoms and characterized the immunomodulatory activity of
DermAll ASIT by measuring cytokine secretion after OVA-stimulation of splenocytes and antibodies from the sera. In allergic mice DermAll
ASIT was as safe as Placebo, balanced the allergen-induced pathogenic TH2-polarized immune responses, and decreased the clinical
symptoms by 52% [32%, 70%] compared to Placebo. These studies suggest that DermAll ASIT is safe and should significantly improve the
immunopathology and symptoms of allergic diseases.
From the Clinical Editor: A novel allergen-specific immunotherapy for IgE-mediated allergies is presented in this paper, using an
experimental allergic rhinitis model and a synthetic plasmid pDNA/PEIm nanomedicine expressing ovalbumin as model allergen. Over 50%
reduction of symptoms was found as the immune system's balance was favorably altered toward more TH2-polarized immune responses.
© 2013 Elsevier Inc. All rights reserved.
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World Health Organization, hundreds of millions of people in the
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dx.doi.org/10.1016/j.nano.2013.05.011nasal mucosa. Patients suffer from nasal obstruction, sneezing,
watery rhinorrhea, nasal itching, itchy palate, red and watery
eyes, and from nonphysical symptoms including sleeping
disturbance and emotional problems such as feeling tired,
miserable and irritable.3 AR is a risk factor for asthma, a life-
long chronic inflammatory disorder of the airways that affects
300 million people by impairing their quality of life and
negatively impacting the socio-economic welfare of society.4,5
Currently, the management of AR and other IgE-mediated
allergies involves allergen avoidance, pharmacotherapy and
allergen-specific immunotherapy (ASIT).6-9 Pharmacotherapy is
the State of Art, because it is safe, well tolerated, suppresses the
symptoms and improves the quality of life. However, these drugs
neither cure allergy nor protect from disease progression
including the development of asthma. ASIT is the only
disease-modifying treatment for AR.7,10,11 Currently, highly-specific immunotherapy. Nanomedicine: NBM 2013;9:1245-1254, http://
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a poorly characterized mixture of allergens with other
proteins.7,12 These extracts are administered via different routes.
Presently available ASITs involve weekly subcutaneous and
sublingual administration of increasing doses of such allergen
extracts over a period of several years.13,14 The percentage of
allergic patients undergoing ASIT is low due to the long duration
of the therapy and the risk of severe systemic or local allergic
reactions associated with the administration of the same allergen
causing the disease.15,16
Innovations in ASIT focused partly on alternative delivery of
allergen extracts. In 1957, two groups reported significant
treatment success with epicutaneous immunotherapy (EPIT).
Pautrizel et al repeatedly deposited the allergen extract on a
slightly rubbed epidermis and Blamoutier et al applied the
allergen extract onto extensively scarified area of skin.17,18
Current EPIT involves adhesive tape stripping, other abrasive
methods and penetration enhancers like an occlusive patch
leading to sweat accumulation.19,20 The first randomized placebo
controlled clinical trial of EPIT with grass-allergen extracts
reported significantly stronger amelioration of AR symptom than
Placebo.19 The next dose-escalation study confirmed the efficacy
of this EPIT, but demonstrated a significant risk of systemic
allergic reactions associated with the application of allergen
extract to tape-stripped skin.21 Recently, EPIT has been
investigated with allergen extract formulated in nanoparticles in
animal models.22 Other investigators used intralymphatic
infusion of allergen extract to deliver allergen to the lymph
node and to induce TH1 polarized immune responses.
23
There is a high unmet medical need for a safer and more
effective ASIT to treat IgE-mediated allergic diseases. Here we
describe the preclinical investigations of a novel nanotechno-
logical product, called DermAll ASIT, developed for the
treatment of patients with IgE-mediated allergies. DermAll has
several new features compared to present ASIT: (i) instead of an
allergen extract it contains a plasmid DNA (pDNA) expressing
well characterized molecular allergens; (ii) the pDNA is
formulated to a synthetic pathogen-like nanomedicine to support
delivery and potent expression of the allergen in antigen
presenting cells; (iii) the nanomedicine is administered topically
with DermaPrep device to target DermAll to the draining lymph
nodes and to induce TH1-polarized immune responses.
24-26
Ovalbumin (OVA) is one of the major allergens of chicken
egg white, and egg allergy is one of the most prevalent forms of
food allergy in children.27 To mimic the human IgE-mediated
allergic diseases in mice we selected the OVA-induced AR
model. We sensitized mice with intraperitoneal injection of OVA
protein emulsified in aluminium hydroxide gel to induce TH2-
type immune responses and produce OVA-specific IgE. These
sensitized mice were subsequently challenged by intranasal
administration of OVA solution to provoke allergic symptoms
such as sneezing and nasal rubbing.28 In this mouse model we
tested the safety, immunogenicity and efficacy of DermAll-
OVA, a prototype DermAll nanomedicine made with pDNA
expressing OVA as a molecular allergen.
We present here the proof of concept for DermAll ASIT. We
found that DermAll-OVA treatment was as safe as Placebo and
balanced TH2/TH1 OVA-specific immune responses in allergicmice. This allergen-specific immunomodulating activity ofDermAll
ASIT reduced the clinical symptoms of IgE-mediated AR.Methods
Animals
Female, 8-week-old BALB/c mice were used in the
experiments (Charles River Laboratories, Germany). The mice
were kept on normal diet; food and water were available ad
libitum. Annual care and experimental procedures were carried
out in accordance with the local guidelines of University of
Szeged. The study protocols were approved by the Committee on
the Ethics of Animal Experiments of the University of Szeged.
Plasmid expressing ovalbumin (OVA) as a model allergen
pc-OVA plasmid consists of a pcDNA3 backbone and an
OVA-encoding insert driven by the CMV promoter, kindly
provided by A. Heit.29 For DermAll-OVA manufacturing the
plasmid DNA was amplified using a Qiagen EndoFree Plasmid
GIGA kit, according to the manufacturer's protocol (Hilden,
Germany). Rigorous quality control measurements were per-
formed to analyze the properties of each pDNA batch. The purity
was measured by determination of OD 260/280 ratio and the
integrity by agarose gel electrophoresis to determine the ratio of
nicked and supercoiled DNA content.
Manufacturing DermAll-OVA and Placebo nanomedicine vaccine
The preparation of DermAll-OVA nanomedicine was de-
scribed previously for DermaVir.30 Briefly, 1 mg/mL solutions
of pDNA were mixed with PEIm (13.6 mM solution of linear
22 kDa polyethylenimine containing 3% mannobiose) in the
presence of 6 volume D-glucose solvent. The Placebo vaccine
contained PEIm mixed with solvent.
Particle size measurements
Measurements were performed from samples containing
10 μg/mL pDNA in DermAll-OVA (in triplicates), using
Brookhaven ZetaPALS™ instrument equipped with quartz
cuvette. Parameters: 3 runs, 30 seconds each; dust filter setting:
30; temperature: 25 °C; angle: 90°; wavelength: 659.0 nm;
baseline: auto. All samples are diluted with ultra-pure water.
Zeta potential analysis
Zeta potential analysis measurements were performed using
DermAll-OVA samples containing 10 μg/mL pDNA with
Brookhaven ZetaPALS™ instrument equipped with “four side
clear” plastic cuvette. Parameters: 5 runs, 10 cycles; temperature:
25 °C. All samples were diluted with ultra-pure water.
Biological characterization of DermAll-OVA nanomedicine
The in vitro expression test of the DermAll-OVA nanome-
dicine was performed by transfection of 293 T human cells.
16 μg pDNA/DermAll-OVA was transfected into 5 × 106 cells
in 5 mL DMEM culture medium (Invitrogen, DMEM, 1% FBS,
1% L-glutamine, 1% Penicillin-Streptomycin) and incubated for
Figure 1. DermAll ASIT prevented acute allergic symptoms. (A) Experimental design: mice were treated with DermAll-OVA or Placebo six times weekly
(DermAll-OVA ASIT), then sensitized (S) and subsequently challenged (C) with OVA. (B)DermAll-OVA reduced nasal symptoms (NS) compared to Placebo.
(C) OVA-specific IgE levels. Data are presented as median and interquartile range.
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secreted and intracellular OVA expression supernatants and cells
were harvested. Cells were lysed in 1 mL lysis buffer (1% SDS,
150 mM Tris pH: 7.5) and Western blot was performed. 1 μL of
the collected supernatant/cell lysate was analyzed on 10%
polyacrylamide SDS-gel. Ovalbumin mouse anti-chicken mono-
clonal antibody was used to detect specifically the ovalbumin
antigen (Lifespan Biosciences Inc., cat.: LS-C47187).
Topical DermAll-OVA administration (DermaPrep)
Mice were anesthetized and their fur was removed from the
back by shaving. Then, the skin was prepared by rubbing the skin
20 times with a sponge adopted fromDermaPrep device followed
by tape stripping.26 Total volume of 200 μL DermAll-OVA
(containing 25 μg pDNA) or Placebo was applied on approxi-
mately 20 cm2 area on the prepared skin of each mouse. The
selected dose of pDNA was based on our previous monkey
studies, where 25 μg pDNA containing nanomedicine was
administered on four different skin sites.31 This immunization
procedure has been standardized to ensure the reproducibility,
and avoid serious inflammation and tissue damage.
Safety parameters of DermAll-OVA immunization
To assess the safety of DermAll ASIT body weight and local
adverse reactions at the treatment sites were measured. The body
weights were measured weekly for each mouse during every
preventive and therapeutic studies. The treatment skin site ofDermAll-OVA was investigated before and 24 hours after each
immunization. The gross pathology findings were recorded after
mice were sacrificed.
DermAll-OVA placebo controlled and blinded
immunization protocols
Naïve mice were immunized six times weekly with DermAll-
OVA or Placebo (Figure 1, A). At weeks 6 and 8 mice were
sensitized and at week 10 challenged with OVA for three
consecutive days. Consequently, a blinded operator evaluated the
nasal symptoms (seemethods later). At the end of the study protocol
(week 11) mice were sacrificed and splenocytes were collected.
Sensitization with OVA protein
25 μg/mouse OVA (grade III. Sigma-Aldrich) diluted by
sterile phosphate buffered saline (PBS) containing 1 mg/mouse
aluminium hydroxide gel (Sigma-Aldrich). 300 μL of this
solution was injected intraperitoneal to unanesthetized mice.
Nasal challenge with OVA protein
500 μg/mouse OVA was diluted in 10 μL PBS. 5 μL of this
solution was administered on each nasal cavity of the mouse for
three consecutive days.
Quantitative assessment of clinical symptoms
On the third day of challenge nasal symptoms were evaluated
by counting the number of sneezing and nasal rubbing for
Figure 2. Characterization of DermAll nanomedicine. (A) Cartoon represents the pathogen-like pDNA/PEIm nanomedicine showing the PEIm envelop and the
condensed pDNA core.30 DermaPrep topical administration involves a standardized skin preparation that interrupts the stratum corneum and activates epidermal
LCs causing a mild, transient erythema. Activated LCs take up the nanoparticles and migrate to the lymph nodes. In the lymph nodes LCs express the DNA-
encoded antigens and present epitopes to naïve T cells.26 (B) Size distribution of the nanoparticles of DermAll-OVA nanomedicine. (C) Expression of OVA
detected byWestern blot. Lanes: transfected cell lysates (1-2) and supernatants (3-4): control (1); pcOVA (2); Control (3); pcOVA (4); Perfect ProteinMarker (5).
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Counting of the symptoms was performed by a blinded operator.
Detection of OVA-specific IgE, IgG1 and IgG2a in serum
Serum samples were collected and sera were kept frozen at −
20 °C until analysis. OVA-specific IgE, IgG1 and IgG2a levels
were analyzed with ELISA Quantitation Kit according to the
manufacturer's instruction (Bethyl Laboratories). Briefly, 96-
well microplate was coated with 5 μg/well ovalbumin (grade V.,
Sigma-Aldrich) dissolved in normal saline and incubated
overnight at 4 °C. The plate was then washed then blocked
with 1% bovine serum albumin at 37 °C for 1 hour. Serum
samples were diluted (1:5 for IgE; 1:10 for IgG1 and IgG2a) and
added into the wells and incubated for 1 hour. After washing,
horseradish peroxidase conjugate solution (1:20,000 dilutions)
was added and incubated for 1 hour. Enzymatic activity was
measured with enzyme substrate solution (equal volumes of
Tetramethylbenzidine (TMB) peroxidase substrate and peroxi-
dase solution) for 30 min at 37 °C. The absorbance was
measured at 450 and 620 nm using an ELISA plate reader
(Thermo, Elektroscan).
Cytokine assays
4 × 106 splenocytes were plated in 6-well plates in 2 mL
RPMI 1640 (GIBCO, Life Technologies) supplemented with
10% heat-inactivated Fetal Bovine Serum (Thermo ScientificHyclone), 5% penicillin/streptomycin, 5% L-Glutamine and
0,1% 50 mM Mercapto-ethanol (Sigma-Aldrich). Splenocytes
were activated with 50 μg/mL OVA (grade V., Sigma-Aldrich)
or culture medium (assay control) and incubated at 37 °C in CO2
thermostat. After 72 hours, supernatants were collected and
stored at −20 °C until further analysis.
OptEIA Elisa Set was used to measure the levels of IL-4, IL-
5, IL-10, and IFN-γ according to the manufacturer's instructions
(Becton Dickinson). Briefly, plates were coated overnight at
4 °C with the anti-mouse monoclonal antibody. The plates were
washed then blocked with 10% fetal bovine serum for 1 hour.
Samples and standards were added and incubated for 2 hours.
Then plates were incubated with biotinylated anti-mouse
monoclonal antibody and streptavidin-horseradish peroxidase
conjugate of a 1:250 dilution for 1 hour. Antigen-antibody
complexes were detected with a substrate solution (containing
TMB and hydrogen peroxide). The absorbance was measured at
450 and 620 nm using an ELISA reader (Thermo, Elektroscan).
Data were calculated as the cytokine concentration in the
supernatants of OVA-activated cells minus in assay controls. In
the therapeutic immunization protocol assay controls were not
deducted from OVA-activated samples.
Statistical analyses
Statistical analyses were performed by using SAS 9.2 (SAS
Institute Inc., Cary, NC, USA). Nasal symptoms were analyzed
Figure 3. Allergen-specific immune responses are balanced after DermAll ASIT. Mice were treated with DermAll-OVA ASIT, subsequently sensitized and
challenged with OVA (see Figure 2, A). OVA-specific IL-4, IL-5, IFNγ and IL-10 responses are presented as median and interquartile range.
1249E. Garaczi et al / Nanomedicine: Nanotechnology, Biology, and Medicine 9 (2013) 1245–1254with Wilcoxon rank sum test for the preventive immunization
protocols and with Hollander's test for the therapeutic protocol.
For estimating treatment effects we used Hodges–Lehmann
point estimate with exact 95% confidence interval on the log-
transformed data. All other comparisons were made with
Wilcoxon rank sum test. Cytokine data are presented in median
and quartiles (Q1-Q3). In all cases, P values less than 0.05 were
considered statistically significant.Results
Characterization of DermAll-OVA nanomedicine
We constructed and characterized DermAll-OVA pathogen-
like nanomedicine consisting of a synthetic mannosylated
polyethylenimine (PEIm) “envelop” and an OVA encoding
pDNA “core” (Figure 2, A). The zeta potential of DermAll-
OVA was +8.6 ± 6.9 mV demonstrating that the cationic PEIm
totally encapsulated the condensed anionic pDNA. The mean
effective diameter of the DermAll-OVA nanomedicine was
141 ± 18 nm, with a bimodal size distribution containing two
discrete size ranges of nanoparticles (Figure 2, B). We described
earlier that the shape and structure of the two nanoparticle
populations were identical and their biological functions were
the same.30 These nanoparticles have the appropriate size for
receptor mediated entry to Langerhans cells as they are in the
virus size range of 50-500 nm.
We investigated the expression of OVA after transfecting
293 T human cells with DermAll-OVA nanomedicine. OVA
expression was detected by Western blot as a 45 kDa protein
both intracellularly and in the supernatant confirming that OVA
was secreted and had the attached carbohydrate chain required
for correct protein folding in the cells (Figure 2, C).32
DermaPrep medical device (CE-marked) utilizes a topical
immunization procedure developed for LCs targeting nanome-
dicine administration in human subjects.26 This procedure was
adopted in our mice study to provide clinically relevant safety,
immunogenicity and efficacy results. The maximum dose pDNA
(25 μg) that corresponds to 5 × 1012 nanoparticles wasadministered topically per mice. The novel mechanism of action
of a related pDNA/PEIm nanomedicine (DermaVir) has been
previously characterized in mice, macaques, rabbits and human
subjects (Figure 2, A).25
DermAll ASIT prevents the induction of allergic symptoms
To assess the preclinical efficacy of DermAll ASIT we
developed an animal model relevant to human AR. During our
preliminary experiments we have worked out a sensitization and
challenge protocol inmice that resulted in nasal symptoms similar
to the clinical symptoms of AR in human subject. We quantified
these nasal symptoms by counting the sneezing and nasal rubbing
for ten minutes after allergen challenge. We interpreted the
reduced quantity of rubbing and sneezing after DermAll ASIT as
a clinically relevant improvement of AR symptoms.
In our previous experiments, we found that repeated DermAll-
OVA immunizations three times biweekly were not sufficient to
prevent allergic sensitization in naïve mice (data not shown). Next
we treated naïve mice weekly with DermAll-OVA and Placebo for
six times. One week after the final immunization, mice were
sensitized and subsequently challenged with OVA and the nasal
symptoms were quantified (Figure 1, A). The median of sneezing
and nasal rubbing in the Placebo group was 48 (38-63). In contrast,
mice treated with DermAll-OVA ASIT had significantly less 20
(19-33) nasal symptoms (P b 0.001) (Figure 1, B). Our results
suggested the disease-modifying property of DermAll ASIT,
characterized by 52% [32%, 70%] reduction of the AR symptoms.
Conventional ASITs induce a transient increase in IgE
levels followed by a gradual decrease over months and years
of treatment.33,34 However, it was also shown that the level of
allergen-specific IgE did not correlate with the clinical
symptoms in allergic patients.35 We found that DermAll-
OVA ASIT decreased by 55% [12%, 75%] the OVA-specific
IgE production after the first sensitization (week 8). IgE levels
were 22 ng/mL (16-26) in the DermAll-OVA group and 51
(27-73) in the Placebo group (P = 0.005) (Figure 1, C). One
week after the second sensitization (week 9) the median IgE
levels increased to 81 ng/mL (67-101) in the DermAll-OVA
group and 78 (66-101) in the Placebo group (P = 0.842). The
Figure 4. DermAll ASIT in allergic mice. (A) Experimental design: Mice were sensitized (S) two times and subsequently challenged (C) with OVA. These
allergic mice were treated six times biweekly with DermAll-OVA or Placebo. Two weeks later mice were challenged again and nasal symptoms (NS) were
quantified. (B) Nasal symptoms before and after DermAll-OVA and Placebo ASIT. P = 0.625 was calculated by Hollander's test.
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the sensitization suggested that DermAll ASIT could modulate
the allergen-induced IgE responses.
The levels of OVA-specific IgG1 and IgG2a between the 2
groups were found to be comparable during the sensitization at
week 8 and 9 (data not shown).
To study whether the weekly DermAll-OVA administration
schedule was essential for the clinical benefit we doubled the
time between immunizations. Naïve mice were immunized 6
times biweekly with DermAll-OVA and Placebo. Four weeks
after the final immunization, mice were sensitized and
subsequently challenged with OVA. In this experiment the
median number of AR symptoms was 96 (89-103) in the
Placebo and 58 (52-76) in the DermAll-OVA group
(P b 0.001) demonstrating a statistically significant treatment
effect, which can be quantified by a 36% [20%, 49%]
reduction of the AR symptoms (see Figure in Supplementary
Materials). This result confirmed the disease modifying
property of DermAll-OVA nanomedicine.
DermAll ASIT prevents pathogenic TH2-polarized T cell
responses to allergen exposure
Presently available conventional ASITs are associated with an
immune deviation in favor of TH1 responses with an over-
production of IFNγ.11,13 We hypothesized that DermAll ASIT
would balance allergen-specific T cell responses resulting in the
modification of the allergic symptoms. To determine the immune
modulating effect of DermAll-OVA we measured the OVA-specific T cell responses after sacrificing the mice (week 11) in
the experiment depicted in Figure 1, A.
To assess the TH2 responses we measured both IL-4 and IL-5.
The OVA-specific IL-4 responses in the DermAll-OVA and the
Placebo groups were 63 pg/mL (38-104) and 256 pg/mL (184-
373), respectively (P = 0.0004) (Figure 3). The OVA-specific
IL-5 responses were 212 pg/mL (150-254) in the DermAll-
OVA, and 303 pg/mL (220-347) in the Placebo group (P =
0.027) (Figure 3). These data showed that DermAll-OVA
induced a 75% [51%, 86%] decrease in IL-4 and a 28% [0%,
49%] decrease in IL-5 secretion and suggested that DermAll-
OVA prevented the development of pathogenic allergen-induced
TH2-type immune responses.
To assess the TH1 responses we measured IFNγ levels.
The median of OVA-specific IFNγ responses was 1,541 pg/
mL (1,286-1,599) in the DermAll-OVA group and 939 (577-
1,610) in the Placebo group (P = 0.297) (Figure 3). These
results demonstrated that the prevention of allergen-induced
TH2-polarized immune response by DermAll ASIT did not
cause a TH1-type pathogenic immune activation and
suggested that DermAll ASIT balanced the allergen-specific
T cell responses.
To assess the immunomodulation we measured the pleiotro-
pic cytokine IL-10. The OVA-specific IL-10 responses in the
DermAll-OVA and Placebo control groups were 989 pg/mL
(765-1,250) and 1,825 pg/mL (1,778.6-2,287), respectively
(P = 0.002) (Figure 3). Our results showed that DermAll-OVA
led to a significant reduction of IL-10 production in allergic mice.
Figure 5. DermAll ASIT facilitates the immunological recovery from allergic response. Allergic mice were treated with DermAll-OVA and Placebo ASIT and
challenged with OVA (see Figure 4, A). OVA-specific IL-4, IL-5, IFNγ and IL-10 responses are presented as median and interquartile range.
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during acute allergic symptoms
Next, we evaluated the efficacy of DermAll ASIT during
acute allergic symptoms. OVA allergy was induced in mice with
sensitization and challenge as depicted in Figure 4, A. These
highly symptomatic allergic mice were treated six times
biweekly either with DermAll-OVA or Placebo. Two weeks
after the final immunization mice were challenged again to
measure the treatment effect of DermAll-OVA.
The limitation of this animal model was that most of the mice
treated with Placebo recovered after 12 weeks without allergen
exposure. Within these 12 weeks of recovery the median
sneezing and nasal rubbing in the Placebo group decreased
20% from 64.5 (54-69) to 52 (31-65) (Figure 4, B). Similarly, in
the DermAll-OVA group the nasal symptoms decreased 32%
from 61.5 (38-71) to 42 (29-43) (Figure 4, B). The speed of
recovery of AR symptoms measured between DermAll-OVA
and Placebo ASITs was statistically not significant (P = 0.625).
Repeated experiments showed similar results. These results
suggested that DermAll ASIT administered during acute allergy
might cause a faster recovery of AR symptom but our results did
not prove the treatment efficacy.
To investigate the immunomodulatory effect of DermAll-OVA
ASIT on symptomatic mice we measured the OVA-specific T cell
cytokine responses. Interestingly, we found that the TH2-type
cytokine production was significantly lower in allergic mice
treated with DermAll-OVA compared to Placebo. The OVA-
specific IL-4 responses in the DermAll-OVA and Placebo control
groups were 168 pg/mL (141-196) and 349 (270-393), respec-
tively (P = 0.001) (Figure 5). The median of OVA-specific IL-5
responses was 1,147 pg/mL (798-1,431) in the DermAll-OVA
group and 1,555 pg/mL (1,119-1,877) in the Placebo control group
(P = 0.026) (Figure 5). These results suggested that DermAll
treatment facilitated the immunological recovery from AR.
We measured the levels of a TH1-type cytokine, IFNγ. The
OVA-specific IFNγ responses in the DermAll-OVA and the
Placebo groups were 1,636 pg/mL (1,493-1,679), and 1,633 pg/
mL (1,627-1,674), respectively (P = 0.985) (Figure 5). Theseresults confirmed that DermAll ASIT treatment results in
balanced allergen-specific immune responses.
We measured the secretion of IL-10. We found that the OVA-
specific IL-10 responses were 1,349 pg/mL (1,134-1,663) in the
DermAll-OVA group, and 1,969 pg/mL (1,739-2046) in the
Placebo control group (P = 0.002) (Figure 5). These results
confirmed that DermAll ASIT led to a significant reduction in
IL-10 secretion in allergic mice.
Safety features of DermAll-OVA immunization
Current ASITs performed with allergen extracts are associ-
ated with the risk of severe allergic reactions.15,16 Specifically,
EPIT of allergic patients with allergen extracts induced eczema at
the vaccine application site and was associated with systemic
allergic reactions.19,21 Therefore, one of the main objectives in
DermAll development was to improve the safety of the presently
available ASITs.
The body weights were measured weekly for each mouse
during every preventive (Figure 1) and therapeutic (Figure 4)
study. We found that DermAll ASIT did not cause weight loss
in mice. No abnormalities were seen during necropsy after
external, abdominal and thoracic examinations in DermAll-
OVA immunized mice (data not shown). These results showed
the safety features of DermAll-OVA and suggested that
DermAll ASIT would not cause systemic side effects in
human subjects.
To determine the local skin reactogenicity (any adverse
reaction on the skin), the treatment skin site of DermAll-OVA
was investigated before and 24 hours after each immunization
procedure. No erythema, oedema, eczema or other long-lasting
skin reactions were observed after repeated DermAll immuni-
zations to highly allergic mice (Figure 4). There were no
differences in local skin reactogenicity between DermAll and
Placebo groups in naïve mice either (Figure 1). Local, transient
skin irritation seen immediately after DermAll application was
due to the DermaPrep skin preparation (rubbing and tape
stripping) in both groups. The same results were found with
DermaVir HIV-specific immunotherapy during both preclinical
Figure 6. Potential disease modifying activity of DermAll ASIT. Allergen exposures cause pathogenic TH2-polarized immune responses. We hypothesize that
allergy might be cured by balancing the TH2/TH1 responses to allergens. The immunological activity of DermAll was associated with clinical improvement
measured as the reduction of allergic symptoms. Based on the results in mouse model we propose that DermAll might be most effective when administered in an
allergen-free period to increase the immunological and clinical recovery during the following allergen exposures. However, we expect a faster recovery in the
absence of safety problems when we continue DermAll during the period of allergen exposures to keep balancing the allergen-specific immune responses.
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ASIT might have excellent safety features in allergic human
subjects.Discussion
We introduced here DermAll, a novel ASIT, developed to
improve both the safety and the efficacy of presently available
allergen extract-based ASITs. DermAll ASIT is a needle-free
patch treatment with a nanomedicine containing an allergen-
encoding pDNA. DermAll ASIT has two components: a
synthetic pDNA/PEIm nanomedicine for LC-targeted nuclear
delivery of pDNA to express epitopes in the lymph nodes, and a
medical device (DermaPrep) for topical administration of the
nanomedicine. The topical administration delivers the pathogen-
like nanomedicine into the epidermis to target LCs. These
professional antigen presenting cells, specialized for uptake of
pathogens, pick up the nanoparticles and migrate to the draining
lymph nodes.24-26 Allergen exposure induces IgE production in
plasma cells and an increased TH2-type cytokine production in
lymphoid tissues and nasal mucosa.13 We hypothesized that the
allergen-specific TH1-type immune response induced by Der-
mAll ASIT balances the immune deviation caused by the
allergens and decreases the nasal symptoms of AR.
DermAll is the pipeline product of DermaVir HIV-specific
immunotherapy that was feasible and well tolerated in almost
100 HIV-infected subjects.24-26 Three clinical trials showed that
DermaVir therapy was as safe as Placebo and induced robust
antigen-specific TH1 polarized immune responses. We found
that DermAll ASIT was safe; it showed no systemic side effects
and did not induce pathogenic immune responses. The local skin
reactogenicity of DermAll ASIT was comparable to Placebo in
both naïve and allergic mice. Similar safety and immunogenicity
profile was established in animal models and human subjects
with DermaVir HIV-specific immunotherapy. The human data
with DermaVir validate the immunogenicity of DermAllobtained from mouse model; however the safety and efficacy
should be tested in allergic patients.
DermaVir and DermAll are the same pDNA/PEIm nanome-
dicines, the same chemical entities, and the only difference
between them is the sequence of the pDNA that ensures the
antigen specificity of the nanomedicine. Both DermaVir and
DermAll are administered topically to target the pDNA-encoded
antigens to LCs.24 These nanomedicine-containing LCs migrate
to the lymph nodes, express the antigens and present the epitopes
to naïve T cells (Figure 2). We showed potent in vitro expression
of OVA from the DermAll nanomedicine confirming previous
results obtained with pcOVA plasmid in vivo tested in mice.29
We have previously demonstrated nanomedicine-derived gene
expression in the draining lymph nodes after topical administra-
tion of a pDNA/PEIm nanomedicine in BALB/c and C57BL/6
mice and macaques.24 Antigen expressing LCs were mainly
located in the paracortical area of the lymph node, which is also
referred to as the T cell area.
We demonstrated that DermAll ASIT prevented the induc-
tion of clinical symptoms of AR in a mouse model. We found
that at least six repeated DermAll-OVA treatments were
required to prevent the clinical symptoms. These repeated
DermAll immunizations administered either weekly or biweekly
significantly protected the animals from the development of
allergic symptoms (Figure 1). In contrast, we could not
demonstrate statistically significant clinical benefit when
DermAll ASIT was used to treat highly allergic, symptomatic
animals (Figure 4). Unfortunately, longer treatment period of
allergic mice also failed to demonstrate clinical efficacy, since
even in the absence of any treatment mice recovered within
12 weeks. Most importantly, DermAll ASIT prevented TH2-
polarized allergic immune responses and also facilitated the
immunological recovery in mice with acute allergic symptoms.
Based on these results we propose that repeated DermAll ASIT
would be a safe and effective disease modifying treatment for
allergic patients.
1253E. Garaczi et al / Nanomedicine: Nanotechnology, Biology, and Medicine 9 (2013) 1245–1254DermAll ASIT has a novel mechanism of action to balance
allergen-specific immune responses. DermAll-OVA immuniza-
tion decreased the TH2-type immune responses (IL-4 and IL-5)
both in subsequently sensitized (Figure 3) and in allergic mice
(Figure 5), and promoted a shift of the immune response to a
balanced TH2/TH1 profile.
Conventional ASITs induce a transient increase in specific
IgE levels followed by a gradual decrease over months or years
of treatment. However, it is also known that the level of specific
IgE does not correlate directly with the clinical symptoms in
allergic patients.35 We found that DermAll immunization did not
induce the production of OVA-specific IgE, IgG1 or IgG2a in
naïve mice (data not shown). The decreased OVA-specific IgE
production during the sensitization in preventively immunized
mice suggested that DermAll ASIT could modulate the allergen-
induced IgE responses (Figure 1).
Our proposed treatment of allergic patients with DermAll
ASIT is summarized in Figure 6. Repeated allergen exposures
induce pathogenic type 2 cytokine responses and allergic
symptoms in sensitized subjects. Based on our preclinical results
DermAll ASIT should balance the allergen-induced pathogenic
TH2-polarized immune responses and prevent the development
of allergic symptoms. We found that immediately after allergen
exposure DermAll ASIT was less effective in reducing allergic
symptoms but it promoted significantly the immunological
recovery. Based on our preclinical data, we recommend starting
DermAll ASIT in an allergen-free period to achieve clinically
significant improvement during the following allergen exposure.
However, we expect a faster recovery in the absence of safety
problems when we continue DermAll ASIT during the next
period of allergen exposures because we keep balancing the
allergen-specific immune responses even during symptomatic
period. DermAll ASIT could be also efficient to prevent the
disease progression for example from allergic rhinitis to allergic
asthma. We believe that our novel DermAll immunotherapeutic
approach would be safe and effective not only for the treatment
of AR, but also for other IgE-mediated diseases such as venom or
food allergy.
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